- Home
- STGW vs EWTX Comparison
STGW vs EWTX Comparison
Compare STGW & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- EWTX
- Stock Information
- Founded
- STGW 1980
- EWTX 2017
- Country
- STGW United States
- EWTX United States
- Employees
- STGW N/A
- EWTX N/A
- Industry
- STGW
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- EWTX Health Care
- Exchange
- STGW Nasdaq
- EWTX Nasdaq
- Market Cap
- STGW 1.4B
- EWTX 1.6B
- IPO Year
- STGW N/A
- EWTX 2021
- Fundamental
- Price
- STGW $5.00
- EWTX $22.34
- Analyst Decision
- STGW Buy
- EWTX Buy
- Analyst Count
- STGW 6
- EWTX 10
- Target Price
- STGW $8.46
- EWTX $37.30
- AVG Volume (30 Days)
- STGW 5.1M
- EWTX 1.1M
- Earning Date
- STGW 11-06-2025
- EWTX 11-06-2025
- Dividend Yield
- STGW N/A
- EWTX N/A
- EPS Growth
- STGW 1954.71
- EWTX N/A
- EPS
- STGW 0.06
- EWTX N/A
- Revenue
- STGW $2,890,264,000.00
- EWTX N/A
- Revenue This Year
- STGW $4.18
- EWTX N/A
- Revenue Next Year
- STGW $9.16
- EWTX N/A
- P/E Ratio
- STGW $87.40
- EWTX N/A
- Revenue Growth
- STGW 6.75
- EWTX N/A
- 52 Week Low
- STGW $4.03
- EWTX $10.60
- 52 Week High
- STGW $8.18
- EWTX $35.50
- Technical
- Relative Strength Index (RSI)
- STGW 49.83
- EWTX 72.55
- Support Level
- STGW $4.70
- EWTX $19.87
- Resistance Level
- STGW $6.88
- EWTX $24.00
- Average True Range (ATR)
- STGW 0.33
- EWTX 1.52
- MACD
- STGW 0.02
- EWTX 0.50
- Stochastic Oscillator
- STGW 17.33
- EWTX 79.03
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.